Canada markets closed

Replimune Group, Inc. (REPL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.17-0.08 (-0.97%)
At close: 04:00PM EDT
8.49 +0.32 (+3.92%)
After hours: 07:39PM EDT

Replimune Group, Inc.

500 Unicorn Park Drive
Suite 303
Woburn, MA 01801
United States
781 222 9600
https://www.replimune.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees284

Key Executives

NameTitlePayExercisedYear Born
Mr. Philip Astley-Sparke F.S.A.CEO & Director1.07MN/A1971
Dr. Sushil Patel Ph.D.Chief Strategy Officer665.05kN/A1971
Dr. Robert Coffin Ph.D.Founder, President, Chief Research & Development Officer and Director785.89kN/A1965
Ms. Emily Luisa HillChief Financial OfficerN/AN/A1980
Dr. Colin A. Love Ph.D.Chief Operating Officer419.37kN/A1958
Mr. Andrew SchwendenmanChief Accounting Officer & TreasurerN/AN/A1976
Dr. Pamela Esposito Ph.D.Chief Business Officer464.63kN/A1974
Ms. Tanya N. Lewis M.S.Chief Development Operations Officer4.7kN/A1971
Mr. Christopher SarchiChief Commercial OfficerN/AN/A1968
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.Chief Medical OfficerN/AN/A1966
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Replimune Group, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.